medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2015, Number 3

<< Back Next >>

Rev Esp Med Quir 2015; 20 (3)

Pulmonary arterial hypertension

García-Aguilar H, Flores-Arizmendi A, Antúnez-Sánchez S, Salgado-Sandoval A

Language: Spanish
References: 45
Page: 302-311
PDF size: 657.27 Kb.


ABSTRACT

Pulmonary arterial hypertension (PAH) is a syndrome of diverse etiology and pathogenesis; is characterized by a progressive increase in pulmonary artery pressure. In Mexico, to our knowledge, there are no studies documenting the epidemiological and economic burden of PAH. This information is useful for the design of public policies and to inform decision makers, when prioritizing health interventions and allocate resources to address and monitor health problems in the country. Herein, we describe the disease burden and economic impact of care for patients diagnosed with Pulmonary Arterial Hypertension in health institutions in the public sector in Mexico. We propose the need to generate only evidence on disease burden and economic impact of PAH in the institutions of public health sector in Mexico. With this information we can obtain estimates of demographic, socioeconomic, etiologic profiles, health status and treatment patterns of patients diagnosed with PAH, sizing the financial burden on health institutions treating these patients, differing estimates by type of case (incident or prevalent), clinical condition or functional class, type of regimen (monotherapy or combination therapy).


REFERENCES

  1. Channick R, Williamson, Thimothy L. Diagnosis and treatment of pulmonary arterial hypertension. Cardiol Clin 2004;22:441-452.

  2. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl 5):S5-12.

  3. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et al. Pathologic assessment of vasculopaties in pulmonary hypertension. J Am Coll Cardiol 2004;43(Suppl 5):S25-32.

  4. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl 5):S13-24.

  5. Jansa P, Jarkovsky J, Al-Hiti H, Popelova J, Ambroz D, Zatocil T, et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med. 2014;14:45.

  6. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D34–D41.

  7. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension. Anesthesiology. 2003;99(6):1415-32.

  8. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43(7):1149-53.

  9. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003;2(2):123-37.

  10. Peacock A. Pulmonary hypertension. Eur Respir Rev 2013;22(127):20-5.

  11. Sandoval Zárate J. Hipertensión Arterial Pulmonar. Archivos de Cardiología de México 2006;76(Supl. 2):S2,69-75.

  12. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792–800.

  13. Cool CD, Stewart JS, Werahera P. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999;155:411-419.

  14. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107(2):216-23.

  15. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, et al. End points and clinical trial designs in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl 5):48S-55S.

  16. Galie N. Do we need controlled clinical trials in pulmonary arterial hypertension? Eur Respir J 2001;17(1):1-3.

  17. Committee for Practice Guidelines (CPG) of the European Society of Cardiology. Recommendations for Task Force Creation and Report Production A document for Task Force members and expert panels responsible for the creation and production of Guidelines and Expert Consensus Documents Committee for Practice Guidelines (CPG) of the European Society of Cardiology; 2003. Disponible en: http://www.escardio.org.

  18. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl 5):S81-8.

  19. l Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96(9):2782-4.

  20. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327(2):76-81.

  21. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70(4):580-7.

  22. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic druginduced pulmonary hypertension. Chest 1997;112(3):714-21.

  23. Weatherford DA, Sackman JE, Reddick TT, Freeman MB, Stevens SL, Goldman MH. Vascular endothelial growth factor and heparin in a biologic glue promotes human aortic endothelial cell proliferation with aortic smooth muscle cell inhibition. Surgery 1996;120(2):433-9.

  24. Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P, et al. Nocturnal oxygen therapy in patients with the eisenmenger syndrome. Am J Respir Crit Care Med 2001;164(9):1682-7.

  25. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327(2):76-81.

  26. Rich S, Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for shortterm drug testing. J Am Coll Cardiol 1991;18(5):1323-7.

  27. Sitbon O, Humbert M, Ioos V. Who benefits from longterm calciumchannel blocker therapy in primary pulmonary hypertension? Am J Resp Crit Care Med 2003;167:A440.

  28. Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genthner D, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114(3):787-92.

  29. Naeije R, Vachiery F. Medical treatment of pulmonary hypertension. Clin Chest Med 2001;22(3):517-27.

  30. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96(9):2782-4.

  31. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Rev Esp Cardiol 2005;58:523-66.

  32. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003;2(2):123-37.

  33. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132(6):425-34.

  34. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302.

  35. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112(7):485-91.

  36. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999;116(4):914-20.

  37. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-4.

  38. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000;35(1):176-82.

  39. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled Iloprost in severe pulmonary hypertension. N Engl J Med 2002;347(5):322-9.

  40. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41(12):2115-25.

  41. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61(2):227-37.

  42. Clozel M, Breu V, Gray GA, Loffler BM. In vivo pharmacology of Ro 462005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol 1993;22:S377-9.

  43. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl 5):62S-7S.

  44. Ghofrani HA, for the Sildenafil 1140 Study Group. Efficacy and safety of sildenafil citrate in pulmonary arterial hypertension: results of a multinational, randomized, doubleblind, placebocontrolled trial. Am Coll Chest Phys 2004.

  45. Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003;124(6):2087e92.




2020     |     www.medigraphic.com